Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Albert Bourla

Pfizer will spend $43 billion to acquire Seagen

Pfizer will spend about $43 billion to buy Seagen and broaden its reach into cancer treatments, the pharmaceutical giant said Monday

The Independent UK

Pfizer’s Susan Rienow: from Covid to fighting the ‘silent pandemic’

The pharma giant’s UK chief is adding the company’s voice to scientists’ warnings of the dangers of antibacterial resistance

The Guardian - UK

Obesity treatments catch drugmakers’ eyes as sales seen soaring

Three years ago, drugmakers and laboratories around the world responded to the pandemic with Covid-19 vaccines. Now that the urgency has faded, they’re collectively turning attention to an older pandemic: obesity.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer CEO Dismisses Reports of a Paxlovid Generic for China

The U.S. pharmaceutical giant is working on starting domestic production of the branded version of the Covid drug in the first half of this year

Caixin Global

Paxlovid has been free so far. Next year, sticker shock awaits

Nearly 6 million Americans have taken Paxlovid for free, courtesy of the federal government. The Pfizer pill has helped prevent many people infected with COVID-19 from being hospitalized or dying, and it may even reduce the risk of developing long COVID. But the government plans to stop footing the bill…

Tribune News Service

Mark Zuckerberg Takes Blame As Meta Lays Off 13% Of Workforce, Elon Musk's Tesla Stock Sale May Not Sit Well With Investors, Netflix Eyes Sports Leagues: Top Stories Wednesday, Nov. 09

Benzinga

Pfizer’s COVID cash powers a ‘marketing machine’ on the hunt for new supernovas

For drugmaker Pfizer, a fortune amassed in the COVID pandemic is now paving the path to pharma nirvana: a weight loss pill worth billions.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

Pfizer is on the hunt for new blockbuster drugs, backed by its COVID fortune

While sales of its COVID vaccines are falling, Pfizer plans to triple the price of the shots and use its bonanza from government contracts to buy and develop new blockbusters.

Fortune

With COVID on the retreat, are Halloween, Thanksgiving and winter holiday gatherings safe?

LOS ANGELES -- COVID-19 has scrapped many large holiday celebrations during the last two years.

Los Angeles Times

Coronavirus subvariant BA.2.75.2 appears in LA County

LOS ANGELES — The omicron subvariant BA.2.75.2 — a newer coronavirus strain some scientists fear could be problematic — has arrived in Los Angeles County.

Los Angeles Times

iPhone 14 Popular In China?, Netflix May Lose Comics, Elon Musk's Starlink Slows, Byron Allen Faces $10B Lawsuit And More Top Financial Media Stories Monday, Sept. 26

Bloomberg

Benzinga

Pfizer CEO tests positive for Covid

Albert Bourla has already received four doses of the Pfizer-BioNTech vaccine

The Independent UK

Pfizer CEO tests positive for COVID-19, has mild symptoms

The top executive at Pfizer, a leading producer of COVID-19 vaccines, has tested positive for the virus and says he is experiencing very mild symptoms

The Independent UK

Watchdog reprimands EU executive for failing to share Von der Leyen texts

European Commission ‘gave no good reason’ why its president’s messages with Pfizer were not released

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

Tribune News Service

How Pfizer won the pandemic, reaping outsize profit and influence

The grinding two-plus years of the pandemic have yielded outsize benefits for one company — Pfizer — making it both highly influential and hugely profitable as COVID-19 continues to infect tens of thousands of people and kill hundreds each day.

ABC News

Malcolm Roberts says a rule change at the WHO 'would have decimated' Australia's sovereignty. Is he correct?

The One Nation senator has continued to push the baseless claim that Australia could be forced to adopt restrictive health measures by the World Health Organization.

The Independent UK

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

Asharq Al-Awsat

Pfizer Offers to Sell Medicines at Cost to Poorest Countries

US pharmaceutical giant Pfizer on Wednesday said it would sell its patented drugs on a not-for-profit basis to the world's poorest countries, as part of a new initiative announced at the World Economic Forum in Davos. "The time is now to begin closing this gap" between people with access to…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Pfizer To Sell 23 Patented Drugs, Vaccines At Lower Prices To Poorer Countries

Pfizer Inc (NYSE:PFE) will sell over 20 patent-protected drugs and vaccines at not-for-profit prices to 45 of the world's poorest countries. Under the program, Pfizer will begin shipping the medicines first to Ghana, Malawi, Rwanda, Senegal, and Uganda before the end of this year, Chief Executive Albert Bourla said in an interview. This will…

Bangkok Post

Cambodia, Laos to benefit as Pfizer slashes drug prices for poorest nations

Pfizer Inc plans to sell its entire portfolio of brand-name drugs at cost in as many as 45 lower-income countries, including Cambodia and Laos, one of the most comprehensive and ambitious drug-access programmes ever announced by a large pharmaceutical manufacturer.

Reuters

Pfizer to sell all its patented drugs at nonprofit price in low-income countries

Pfizer Inc will make all of its patented medicines including COVID-19 treatment Paxlovid and big-selling breast cancer drug Ibrance available at a not-for-profit price to 45 of the world's poorest countries, the drugmaker said on Wednesday.

Tribune News Service

Commentary: The US is doing too little to monitor Paxlovid use

Paxlovid, Pfizer’s antiviral treatment for COVID-19, is turning out to be one of the most successful new drugs in pharma history. Prescriptions have increased tenfold since February, and the five-day pill pack accounts for nearly 90% of the COVID-19 oral-antiviral market.

Benzinga

FDA Berates Pfizer CEO's Suggestion To Take More Paxlovid If COVID-19 Symptoms Rebound

The FDA berates Pfizer Inc (NYSE: PFE) CEO Albert Bourla's proposed solution in cases where virus levels rebound after the first course of treatment.

Tribune News Service

FDA contradicts Pfizer’s advice on 2nd course of COVID drug

There is “no evidence” that a second course of Pfizer Inc.’s Paxlovid will help COVID-19 patients whose symptoms return after an initial course of the antiviral, a U.S. Food and Drug Administration official said a day after Pfizer executives advocated the idea.

Axios

Parents of kids under 5 still waiting for COVID shots

The demise of the federal transportation mask mandate was particularly jarring for many parents of children under five anxiously waiting for word on when COVID shots will become available to their kids.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.